Leaders in monolith chromatography



Join us on BIA's seminar in Shanghai, China

BIA will organize a seminar about CIM monoliths for purification and in-process control of macromolecules with an emphasis on gene therapy and vaccines. Date: 2018/9/4; 8:30 am - 12 pm Seminar will be held in 3rd floor VIP room, Building B, Ramada Plaza Hotel, 509 Caobao Road, Shanghai, China

BIA Separations and Biomay collaborate on production and purification of large DNA plasmids

Collaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application

Ajdovščina, Slovenia and Vienna, Austria, 16 May 2018: BIA Separations, a leading biochromatography development and manufacturing company, and Biomay, a contact manufacturer of cGMP biopharmaceuticals, today announced a collaboration on the high-yield production of large DNA plasmids. The companies have co-developed an economical production system for double-digit gram-scale production and purification of plasmids larger than 20,000 base pairs (20kbp) achieving high recovery of 95% supercoiled DNA. The new manufacturing process addresses a major challenge in the scaled manufacture of plasmid DNA and represents a significant step towards the wide application of large DNA plasmids in cell and gene therapy.

The collaboration combines Biomay’s experience in the production of GMP-conform ultrapure pDNA with BIA Separations’ CIM® (Convective Interaction Media) monolithic chromatographic columns. Monoliths support effective purification for plasmids up to at least 60 kbp and are able to maintain high capacity and resolution at high flow rates regardless of the size of the molecules being separated.

The system is commercially available to clients through Biomay´s GMP service offerings.

Aleš Štrancar, CEO of BIA Separations commented: “Monoliths have been well-established for some time as the best purification tools for smaller single-gene plasmids and we are pleased to now adapt them to the purification of larger pDNA molecules. By working with Biomay, we are removing a major obstacle in the field which will allow product developers to proceed with an unlimited array of multi-gene clinical candidates.”

Dr Hans Huber, COO of Biomay added: “The combination of our know-how in pDNA production with BIA’s monolithic columns represent a key enabling step for us to meet our customer´s needs for fast and economic production of large DNA plasmids, such as AAV starting vectors, in quantities required for the clinical development and early market supply of their gene therapy products.”

At BIA Separations E: This email address is being protected from spambots. You need JavaScript enabled to view it. T: +386 (0)59 699 505

Media contact Sarah Jeffery (Zyme Communications) E: This email address is being protected from spambots. You need JavaScript enabled to view it. T: +44 (0)7771 730 919

At Biomay: E: This email address is being protected from spambots. You need JavaScript enabled to view it. T:+43 1 7966296 100